文献速递新生儿儿童神经与发育行为儿童内分泌与遗传代谢

新生儿低血糖与4.5岁时神经发育结局的关联

Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years.
PubMed 文献 · JAMA Pediatr · 2017-01-01

CHYLD前瞻性队列研究纳入614名有低血糖风险的晚期早产和足月儿,发现新生儿低血糖与4.5岁时复合神经感觉损害风险无显著增加,但与执行功能和视觉运动功能不良风险增加相关,且风险随低血糖严重程度、复发或仅间质检测发现而升高。

要点

  • 新生儿低血糖未增加4.5岁时复合神经感觉损害风险(RD 0.01,95%CI -0.07至0.10)。
  • 低血糖与执行功能不良风险增加相关(RD 0.05,95%CI 0.01至0.10;RR 2.32,95%CI 1.17至4.59)。
  • 低血糖与视觉运动功能不良风险增加相关(RD 0.03,95%CI 0.01至0.06;RR 3.67,95%CI 1.15至11.69)。

核心结论

  • 新生儿低血糖与4.5岁时复合神经感觉损害风险无显著增加,但与执行功能和视觉运动功能不良风险呈剂量依赖性增加相关。

研究设计与样本

  • CHYLD研究为前瞻性队列研究,纳入614名胎龄≥32周且有低血糖风险因素的新生儿。
  • 临床医生对新生儿间质葡萄糖浓度设盲,结局评估者对新生儿血糖状态设盲。

主要发现

  • 604名合格儿童中477名(79.0%)完成4.5岁评估,平均(SD)年龄4.5(0.1)岁,女性228名(47.8%)。
  • 280名(58.7%)儿童暴露于新生儿低血糖,其复合神经感觉损害风险差异无统计学意义(RD 0.01,95%CI -0.07至0.10;RR 0.96,95%CI 0.77至1.21)。
  • 低血糖与执行功能不良风险增加相关(RD 0.05,95%CI 0.01至0.10;RR 2.32,95%CI 1.17至4.59)。
  • 低血糖与视觉运动功能不良风险增加相关(RD 0.03,95%CI 0.01至0.06;RR 3.67,95%CI 1.15至11.69)。
  • 严重、复发或临床未检测到(仅间质低血糖)的低血糖儿童风险最高。

关键数值与推荐

  • 低血糖定义为至少1次连续全血葡萄糖浓度<47 mg/dL,严重低血糖定义为<36 mg/dL,复发性低血糖定义为≥3次发作。
  • 间质低血糖发作定义为间质葡萄糖浓度<47 mg/dL持续至少10分钟。
  • 低血糖婴儿接受治疗以维持全血葡萄糖浓度至少47 mg/dL。

临床怎么用

  • 对于有低血糖风险的新生儿,即使临床未检测到低血糖,也应关注其远期执行功能和视觉运动功能。
  • 需开展随机试验以确定基于至少至学龄期神经发育评估的最佳筛查和干预阈值。

局限性

  • 随访评估率为79.0%,存在失访偏倚可能。
  • 研究结论需随机试验验证最佳筛查和干预阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypoglycemia is common during neonatal transition and may cause permanent neurological impairment, but optimal intervention thresholds are unknown. OBJECTIVE: To test the hypothesis that neurodevelopment at 4.5 years is related to the severity and frequency of neonatal hypoglycemia. DESIGN, SETTING, AND PARTICIPANTS: The Children With Hypoglycemia and Their Later Development (CHYLD) Study is a prospective cohort investigation of moderate to late preterm and term infants born at risk of hypoglycemia. Clinicians were masked to neonatal interstitial glucose concentrations; outcome assessors were masked to neonatal glycemic status. The setting was a regional perinatal center in Hamilton, New Zealand. The study was conducted from December 2006 to November 2010. The dates of the follow-up were September 2011 to June 2015. Participants were 614 neonates born from 32 weeks' gestation with at least 1 risk factor for hypoglycemia, including diabetic mother, preterm, small, large, or acute illness. Blood and masked interstitial glucose concentrations were measured for up to 7 days after birth. Infants with hypoglycemia (whole-blood glucose concentration <47 mg/dL) were treated to maintain blood glucose concentration of at least 47 mg/dL. EXPOSURES: Neonatal hypoglycemic episode, defined as at least 1 consecutive blood glucose concentration less than 47 mg/dL, a severe episode (<36 mg/dL), or recurrent (≥3 episodes). An interstitial episode was defined as an interstitial glucose concentration less than 47 mg/dL for at least 10 minutes. MAIN OUTCOMES AND MEASURES: Cognitive function, executive function, visual function, and motor function were assessed at 4.5 years. The primary outcome was neurosensory impairment, defined as poor performance in one or more domains. RESULTS: In total, 477 of 604 eligible children (79.0%) were assessed. Their mean (SD) age at the time of assessment was 4.5 (0.1) years, and 228 (47.8%) were female. Those exposed to neonatal hypoglycemia (280 [58.7%]) did not have increased risk of neurosensory impairment (risk difference [RD], 0.01; 95% CI, -0.07 to 0.10 and risk ratio [RR], 0.96; 95% CI, 0.77 to 1.21). However, hypoglycemia was associated with increased risk of low executive function (RD, 0.05; 95% CI, 0.01 to 0.10 and RR, 2.32; 95% CI, 1.17 to 4.59) and visual motor function (RD, 0.03; 95% CI, 0.01 to 0.06 and RR, 3.67; 95% CI, 1.15 to 11.69), with highest risk in children exposed to severe, recurrent, or clinically undetected (interstitial episodes only) hypoglycemia. CONCLUSIONS AND RELEVANCE: Neonatal hypoglycemia was not associated with increased risk of combined neurosensory impairment at 4.5 years but was associated with a dose-dependent increased risk of poor executive function and visual motor function, even if not detected clinically, and may thus influence later learning. Randomized trials are needed to determine optimal screening and intervention thresholds based on assessment of neurodevelopment at least to school age.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. McKinlay CJD, Alsweiler JM, Anstice NS, et al. Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years. JAMA Pediatr. 2017. PMID: 28783802. doi:10.1001/jamapediatrics.2017.1579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。